SELLAS Life Sciences Group, Inc. SEC filings SLS
SELLAS Life Sciences Group, Inc. has 1,002 filings in SEC EDGAR's recent list, going back to Apr 21, 2011. Its latest annual report, Form ARS, was filed on Apr 23, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 11, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Aug 11, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Apr 23, 2026 | — |
| DEF 14A | Proxy statement | Apr 23, 2026 | Jun 16, 2026 |
| DEFA14A | Additional proxy material | Jun 10, 2025 | — |
| DEFA14A | Additional proxy material | Apr 23, 2025 | — |
| DEF 14A | Proxy statement | Apr 23, 2025 | Jun 17, 2025 |
| DEFA14A | Additional proxy material | Apr 29, 2024 | — |
| DEF 14A | Proxy statement | Apr 29, 2024 | Jun 20, 2024 |
| DEFA14A | Additional proxy material | Apr 28, 2023 | — |
| DEF 14A | Proxy statement | Apr 28, 2023 | Jun 20, 2023 |
| PRE 14A | Preliminary proxy statement | Apr 17, 2023 | Jun 20, 2023 |
| DEFA14A | Additional proxy material | Apr 25, 2022 | — |
| DEF 14A | Proxy statement | Apr 25, 2022 | Jun 8, 2022 |
| DEFA14A | Additional proxy material | Jun 4, 2021 | — |
| DEFA14A | Additional proxy material | Apr 26, 2021 | — |
| DEF 14A | Proxy statement | Apr 23, 2021 | Jun 8, 2021 |
| DEFA14A | Additional proxy material | Jun 3, 2020 | — |
| DEFA14A | Additional proxy material | Apr 24, 2020 | — |
| DEF 14A | Proxy statement | Apr 23, 2020 | Jun 9, 2020 |
| DEF 14A | Proxy statement | Aug 5, 2019 | Sep 10, 2019 |
| PRE 14A | Preliminary proxy statement | Jul 26, 2019 | Sep 10, 2019 |
| DEF 14A | Proxy statement | May 24, 2019 | Jul 12, 2019 |
| DEFA14A | Additional proxy material | May 16, 2018 | — |
| DEFA14A | Additional proxy material | May 1, 2018 | — |
| DEF 14A | Proxy statement | Apr 30, 2018 | Jun 12, 2018 |
| DEF 14A | Proxy statement | Apr 6, 2018 | Apr 25, 2018 |
| PRE 14A | Preliminary proxy statement | Mar 27, 2018 | Mar 27, 2018 |
| DEFA14A | Additional proxy material | Jun 29, 2017 | — |
| DEFA14A | Additional proxy material | Jun 26, 2017 | — |
| DEF 14A | Proxy statement | Jun 9, 2017 | Jul 6, 2017 |
| DEFA14A | Additional proxy material | May 31, 2017 | — |
| PRE 14A | Preliminary proxy statement | May 30, 2017 | May 30, 2017 |
| DEFA14A | Additional proxy material | Apr 20, 2017 | — |
| DEF 14A | Proxy statement | Apr 20, 2017 | Jun 8, 2017 |
| DEF 14A | Proxy statement | Sep 21, 2016 | Oct 21, 2016 |
| PRE 14A | Preliminary proxy statement | Sep 9, 2016 | Oct 21, 2016 |
| DEFA14A | Additional proxy material | Jul 8, 2016 | — |
| DEFA14A | Additional proxy material | Jun 9, 2016 | — |
| DEFA14A | Additional proxy material | Jun 3, 2016 | — |
| DEF 14A | Proxy statement | Jun 3, 2016 | Jul 14, 2016 |
| PRE 14A | Preliminary proxy statement | May 24, 2016 | Jul 14, 2016 |
| DEFA14A | Additional proxy material | Apr 30, 2015 | — |
| DEF 14A | Proxy statement | Apr 30, 2015 | Jun 19, 2015 |
| PRE 14A | Preliminary proxy statement | Apr 20, 2015 | Jun 19, 2015 |
| DEFA14A | Additional proxy material | Apr 30, 2014 | — |
| DEF 14A | Proxy statement | Apr 30, 2014 | Jun 27, 2014 |
| DEFA14A | Additional proxy material | Apr 29, 2013 | — |
| DEF 14A | Proxy statement | Apr 29, 2013 | Jun 28, 2013 |
| PRE 14A | Preliminary proxy statement | Apr 19, 2013 | Jun 28, 2013 |
| DEFA14A | Additional proxy material | Apr 30, 2012 | — |
| DEF 14A | Proxy statement | Apr 30, 2012 | Jun 15, 2012 |
| PRE 14A | Preliminary proxy statement | Apr 18, 2012 | Jun 15, 2012 |
| DEFA14A | Additional proxy material | May 31, 2011 | — |
| DEF 14A | Proxy statement | May 31, 2011 | Jul 15, 2011 |
| PRE 14A | Preliminary proxy statement | May 20, 2011 | Jul 15, 2011 |
Showing 54 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- SLS (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- New York, NY
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1390478
- Former names
- GALENA BIOPHARMA, INC. (until Dec 15, 2017); Galena Biopharma, Inc. (until Dec 15, 2017); RXI PHARMACEUTICALS CORP (until Sep 21, 2011)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.